Enhanced convenience

Liver Assist™ is compatible with XVIVO Insights, a remote complementary monitoring tool available in selected countries. Through XVIVO Insights, perfusion run data is safely made available, allowing clinicians in real-time to monitor the perfusion remotely, see run notifications and easily share and download run data.

COR – Controlled Oxygenated Rewarming | DBD – Donation after Brain Death | DCD – Donation after Circulatory Death | DHOPE – Dual Hypothermic Oxygenation Perfusion | ECD – Extended Criteria Donor | HOPE – Hypothermic Oxygenated Perfusion | NAS – Non-Anastomotic Biliary Strictures | NMP – Normothermic Machine Perfusion | RCT – Randomized Controlled Trial | SCS – Static Cold Storage.

Liver Assist™ is not available in all markets. Please contact XVIVO for more information regarding availability in your specific region. CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use.

Nobody should die waiting for a new organ

Scan this QR-code to get in touch with us!

Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of organ transplantation.

Not all XVIVO products are approved in all markets.

References:

1. van Rijn R, et al. *Hypothermic Machine Perfusion in Liver Transplantation - A Randomized Trial*. N Engl J Med. 2021;384(15):1391-401.
2. Schlegel A, et al. *A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation*. J Hepatol. 2023.
3. Czigany Z, et al. *Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death: Results From a Multicenter Randomized Controlled Trial (HOPE ECD-DBD)*. Ann Surg. 2021;274(5):705-12.
4. Czigany Z, et al. *Improved outcomes after hypothermic oxygenated machine perfusion in liver transplantation–Long-term follow-up of a multicenter randomized controlled trial*. Hepatology Communications. 2024;8(2):e0376.
5. Grat M, et al. *Routine End-ischemic Hypothermic Oxygenated Machine Perfusion in Liver Transplantation from Donors After Brain Death: A Randomized Controlled Trial*. Ann Surg. 2023.
6. Morawski M, et al. *Routine end-ischemic hypothermic machine perfusion in liver transplantation from donors after brain death: results of 2-year follow-up of a randomized controlled trial*. Int J Surg. 2024;110(11): 7003-10.
7. Dutkowski P, et al. *First Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis*. Ann Surg. 2015;262(5):764-70; discussion 70-1.
8. Patrono D, et al. *Outcome of liver transplantation with grafts from brain-dead donors treated with dual hypothermic oxygenated machine perfusion, with particular reference to elderly donors*. Am J Transplant. 2022.
9. Eden J, et al. *Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study)*. J Hepatol. 2024.
10. van Leeuwen OB, et al. *Sequential Hypothermic and Normothermic Machine Perfusion Enables Safe Transplantation of High-risk Donor Livers*. Am J Transplant. 2022.
11. van Leeuwen OB, et al. *Excellent long-term outcome after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation*. J Hepatol. 2023.
12. Lantinga VA, et al. *Reducing cold ischemia time by donor liver "back-table" preparation under continuous oxygenated machine perfusion of the portal vein*. Clin Transplant. 2022;36(8):e14762.
13. van Leeuwen OB, et al. *'Back-to-base' combined hypothermic and normothermic machine perfusion of human donor livers*. Nat Protoc. 2025.
14. Endo C, et al. *Cost-effectiveness of Dual Hypothermic Oxygenated Machine Perfusion Versus Static Cold Storage in DCD Liver Transplantation*. Transplantation. 2024.
15. Brüggenwirth IMA, et al. *Prolonged hypothermic machine perfusion enables daytime liver transplantation - an IDEAL stage 2 prospective clinical trial*. eClinicalMedicine. 2024;68.

XVIVO BV
Bornholmstraat 84 | 9723 AZ Groningen | Netherlands
Tel +31 50 313 1905 | xvivogroup.com

MAR-24779-v.2.0 2025.05

XVIVO

Liver Assist™

Unlock the power of flexibility

XVIVO

Liver Assist™

Unlock the power of flexibility

During the past decade, Liver Assist™ has played a pivotal role in the advancement of machine perfusion.

With customizable settings, it offers the flexibility to choose from various protocols, including DHOPE, HOPE, COR and NMP, which all serve a different purpose – from improving patient outcome, extending preservation time for logistical purposes to increasing organ utilization.

Liver Assist™ is a pressure controlled ex-vivo perfusion system for donor livers. Two separately controlled pump units provide oxygenated perfusion with near physiologic settings where the flow is automatically adjusted to the natural resistance of the organ.

- O_2 Oxygenated
- Temperature controlled perfusion 12°C - 37°C
- 24h Up to 24H cold perfusion to support logistics
- Full cooling mode: <12°C
- Pressure controlled pulsatile (60 bpm) and continuous perfusion
- Functional viability assessment.
- Remote monitoring ready (selected regions only)



Benefits of Liver Assist™

Improved outcomes

Multiple studies, including high impact RCTs, have demonstrated that end-ischemic (D)HOPE using Liver Assist™ significantly improves patient outcomes following deceased donor liver transplantation as compared to SCS[1-9].

REDUCED RISK OF BILIARY COMPLICATIONS
64%
reduced risk of developing NAS in DCD livers[1]

FEWER GRAFT-RELATED COMPLICATIONS
74%
reduction of severe liver graft-related complications*[2]

REDUCED RISK OF GRAFT LOSS
73%
reduced risk of graft loss up to 5 years*[4]

Increased utilization

+70%

Sequential use of DHOPE and NMP enables safe transplantation of initially declined livers with excellent results[10-13].

Cost-effectiveness

-€25,832

Mean reduction in transplant-related costs per patient with DHOPE compared to SCS-alone[14].

Extended preservation time

Liver Assist™ can safely extend the preservation time, offering more time for recipient selection and added flexibility in scheduling of transplant procedures[15].

> "Prolonged preservation with DHOPE could streamline transplantation logistics and reduce organ discards due to logistical constraints by transforming liver transplantation into a semi-elective procedure, minimizing nighttime surgeries."
>
> Brüggenwirth et al., 2024

*in ECD-DBD livers.
For more information regarding clinical evidence, please see our Clinical evidence summary.